Literature DB >> 2846113

Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis.

D Bergqvist1, T Mätzsch, U S Burmark, J Frisell, O Guilbaud, T Hallböök, A Horn, A Lindhagen, H Ljungnér, K G Ljungström.   

Abstract

A prospective randomized double-blind trial was performed comparing conventional low-dose heparin with a low molecular weight heparin fragment for thromboprophylaxis in elective general abdominal surgical patients. The first dose of the heparin fragment was given the evening before surgery, and further doses were given thereafter every evening. There were 1002 analysable patients, 826 having received correct prophylaxis. Of these 1002 patients, 64 per cent were operated on for malignant disease. A total of 20 patients died, 10 in each group. The frequency of deep vein thrombosis was significantly reduced among patients with correct prophylaxis with the heparin fragment (9.2-5.0 per cent, P = 0.02) [corrected]. The frequency of bleeding was 6.7 per cent among the heparin fragment patients and 2.7 per cent among the patients given conventional heparin (P = 0.01), but all bleeds were of minor degree and there was no difference in the reoperation rate for bleeding, or in the transfusion requirements. Local pain at the injection site was reported significantly less often among patients given the heparin fragment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846113     DOI: 10.1002/bjs.1800750920

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  20 in total

1.  Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.

Authors:  Adrienne Heerey; Sanjeev Suri
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Risk-based evaluation of thromboprophylaxis among surgical inpatients: are low risk patients treated unnecessarily?

Authors:  G Roche-Nagle; J Curran; D J Bouchier-Hayes; S Tierney
Journal:  Ir J Med Sci       Date:  2007-06-07       Impact factor: 1.568

Review 3.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

4.  Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis.

Authors:  J Limmer; D Ellbrück; H Müller; E Eisele; J Rist; F Schütze; H Beger; H Heimpel; E Seifried
Journal:  Clin Investig       Date:  1994-11

5.  Preoperative Chemoprophylaxis is Safe in Major Oncology Operations and Effective at Preventing Venous Thromboembolism.

Authors:  Luke V Selby; Mindy Sovel; Daniel D Sjoberg; Margaret McSweeney; Damon Douglas; David R Jones; Peter T Scardino; Gerald A Soff; Nicola Fabbri; Kent Sepkowitz; Vivian E Strong; Inderpal S Sarkaria
Journal:  J Am Coll Surg       Date:  2015-12-15       Impact factor: 6.113

6.  Venous thromboembolic disease in colorectal patients.

Authors:  Michael P McNally; Christopher J Burns
Journal:  Clin Colon Rectal Surg       Date:  2009-02

Review 7.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

8.  Low molecular weight heparin in prevention of perioperative thrombosis.

Authors:  A Leizorovicz; M C Haugh; F R Chapuis; M M Samama; J P Boissel
Journal:  BMJ       Date:  1992-10-17

Review 9.  Low molecular weight heparins. An objective overview.

Authors:  D Hoppensteadt; J M Walenga; J Fareed
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

10.  [Perioperative prevention of thromboembolism with standard heparin and low molecular weight heparin, evaluation of postoperative hemorrhage. A double-blind, prospective, randomized and mono-center study].

Authors:  R Hoffmann; F Largiadèr
Journal:  Langenbecks Arch Chir       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.